首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Breast Cancer-targets And Therapy

Breast Cancer-targets And Therapy杂志,由Dove Medical Press出版,1 issue/year,出版语言English,ISSN:1179-1314,E-ISSN:1179-1314。

投稿咨询
Breast Cancer-targets And Therapy
Breast Cancer-targets And Therapy
Breast Cancer-targets And Therapy
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
4区
影响因子
3.6
CiteScore
5
期刊收录
SCI、SCIE

Breast Cancer-targets And Therapy(中文译名:《乳腺癌-靶点和治疗》),ISSN:1179-1314,EISSN:1179-1314,是Dove Medical Press出版的国际性学术期刊,以1 issue/year形式稳定发行,2026年总发文量约101篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3.6,2025年期刊CiteScore为5,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Breast Cancer-targets And Therapy长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期16 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、Ethiopia、Iran、India、Saudi Arabia、CHINA MAINLAND等为核心发文国家与地区;UNIVERSITY OF GONDARIRCCS EUROPEAN INSTITUTE OF ONCOLOGY (IEO)、CATHOLIC UNIVERSITY OF THE SACRED HEART、JIMMA UNIVERSITY、JORDAN UNIVERSITY OF SCIENCE & TECHNOLOGY、MAYO CLINIC、OAKLAND UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
4区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 132 / 333

60.5

学科:ONCOLOGY SCIE Q3 174 / 333

47.9

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 118 / 322

63.5

学科:ONCOLOGY SCIE Q3 186 / 322

42.39


中国学者近期发文

1
Lipid Metabolism and Breast Cancer Therapy: An Integrative Literature Revie

Author:Gong, Xiongmeiyu; Zhang, Danni; Wen, Zini; Zeng, Jvtao; Tang, Yao; Deng, Junjie; Bin, Yawen

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S575419

2
Discrimination of Triple-Negative Breast Cancer: A Robust Clinical Baseline versus Multimodal Magnetic Resonance Imaging Integrated Models with Assessment of Generalizabilit

Author:Liao, Xueyan; Wu, Xiaomin; Zheng, Junqiong; Lin, Guoliang; Lin, Dandan

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S594356

3
Supportive Intervention for Unmet Needs Among Breast Cancer Patients and Their Spousal Caregivers: A Randomized Controlled Tria

Author:Zhang, Qian; Wang, Shan; Zhang, Jiajia; Chu, Tianyu; Chen, Xian; Ma, Linlin; Zhou, Hui; Wu, Yibo; Xu, Dewu; Jiang, Kai

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S585827

4
IFI44 Orchestrates an IL-10-Driven M2 Macrophage Program in Breast Cancer: An Immune Prognostic Signatur

Author:Wu, Jiahui; Yi, Wang; Liu, Mengting; Li, Yingliang; Zhou, Boxuan; Wu, Ziyun; Cao, Wei; Shi, Qingfeng; Cai, Xiangkai; Xiong, Haiwei

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S579301

5
Analysis of Factors Related to Lymph Node Metastasis Following Neoadjuvant Chemotherapy for Breast Cancer: Correlation Between Plasma Exosomal Circular RNA and Metastasi

Author:Ma, Sushuang; Huang, Yanqiu; Yang, Qingyan; Liu, Xiaoyan; Zhang, Zhiqiang; Yan, Bing

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S588196

6
Visceral and Subcutaneous Fat Deposits Exhibit Distinct Roles in the Initiation and Progression of Breast Cance

Author:Zhang, Yu; Li, Qi; Zhao, Li; Pang, Yi; Li, Lin; Niu, Wei-Wei; Xing, Yu; Liu, Yu; Zhang, Fu-Quan; Fan, Yu-Chen; Bao, Yuan-Yuan; Li, Chun-Wei; Yu, Kang

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S565061

7
Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathwa

Author:Zhao, Jingzhe; Luo, Xiaoshan; Li, Huan; Cheng, Yu; Xie, Su; Lin, Xiangping

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S580570

8
A Brand-New Drainage Fluid Predictor, ICAM-1 for Implant Loss After the Immediate Reconstruction of Breas

Author:He, Chenyang; Jiang, Yezhen; Zhao, Renyang; Liu, Jia; Yang, Haiying; Zhang, Rongqiang; Zhao, Yang

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S585358

9
Efficacy and Safety of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Combined with Chemoimmunotherapy in Locally Advanced Breast Cancer: A Single-Center, Retrospective Pilot Stud

Author:Zhai, Menglan; Bi, Jianping; Ke, Zirui; Hu, Min; Pi, Guoliang; Li, Ying; He, Hanping; Li, Yanping; Zheng, Hongmei; Wu, Xinhong; Verma, Vivek; Shao, Jun; Han, Guang

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S577469

10
Ovarian Escape in Hormone Receptor-Positive Breast Cancer: Mechanisms, Risk Factors, Clinical Consequences, and Management Strategie

Author:Li, Yuelin; Wang, Wenhui

Journal: BREAST CANCER-TARGETS AND THERAPY. 2026; Vol. 18, Issue , pp. -. DOI: 10.2147/BCTT.S586408


在线咨询

Breast Cancer-targets And Therapy

国际简称:BREAST CANCER-TARGET参考译名:乳腺癌-靶点和治疗

年发文量:101 CiteScore:5 是否预警:否 Gold OA文章占比:99.60% 研究类文章占比:80.20%
Breast Cancer-targets And Therapy